Interviews & Articles
San Diego Business Journal
BIOTECH: INKS $670M DEAL TO BOLSTER PIPELINE
Lineage Unveils Cell Programs
May 9, 2022
This Week in Hearing
Cell Therapy Treatment for Hearing Loss: Interview with Lineage Cell Therapeutics CEO, Brian Culley
Apr 21, 2022
Discussing developing and commercializing cell therapies, competing against Elon Musk’s Neuralink, and the future of cell therapy.
Mar 23, 2022
Making the Cut Podcast
Discussing Lineage’s exclusive worldwide collaboration and license agreement with Roche and Genentech for the development and commercialization of OpRegen
Feb 14, 2022
The Bio Queen Podcast
$LCTX had the privilege of being the debut company profiled on @Biotech_SD’s new YouTube show.
Nov 18, 2021
Pounding the Table Podcast
Nat Harooni of the Pounding The Table Network exclusive interview with Lineage CEO Brian Culley.
Aug 25, 2021
The Clinical Research Circle
Lineage Cell Therapeutics $LCTX Stock CEO Reveals Updates and Progress On the Amazon of Cell Therapy
Aug 25, 2021
Retinal Tissue Restored in Patients with Dry AMD, Heralding Paradigm Shift
BioSpace article featuring Lineage Cell Therapeutics
Jun 14, 2021
Advancing a Pipeline of Off-The-Shelf Cell Therapies – Jun 01, 2021
Presentations from specific events, conferences, or showcases
Lineage Cell Therapeutics – Noble Capital Markets’ Eighteenth Annual Investor Conference
Apr 20, 2022
Advances in the Clinical Development of Oligodendrocyte Progenitor Cells to Treat Spinal Cord Injury
Apr 05, 2021
H.C. Wainwright BIOCONNECT Conference
Jan 10, 2022
Proprietary Cell Therapy Platform – Lineage Presents at GCFF
Sep 30, 2021
OpRegen Presentation at H.C. Wainwright & Co. Ophthalmology Virtual Conference
Aug 17, 2021
Eyecelerator 2021: Retina Clinical Trials: Meet the Innovators Who Are Changing the Game
Jun 07, 2021
Key opinion leaders discuss topics related to Lineage’s clinical programs
Therapeutic Expert Call to Discuss OpRegen Phase 1/2a Study Interim Results (2020 American Academy of Ophthalmology Update)
Nov 17, 2020
Review of the pathogenesis of AMD and the pathways to CNV and GA
Jordi Monés, M.D., Ph.D., Director, Institut de la Màcula and Director, Principal Investigator and Founder, Barcelona Macula Foundation
New Retina Radio with Christopher D. Riemann, M.D.
Vitreoretinal Surgeon and Fellowship Director, Cincinnati Eye Institute
Jun 22, 2020
OpRegen® – A Discussion of Retinal Tissue Regeneration in Dry-AMD with Geographic Atrophy
Jun 08, 2020
Therapeutic Expert Call to Discuss OpRegen Phase 1/2a Clinical Study Results
Christopher D. Riemann, M.D. Vitreoretinal Surgeon and Fellowship Director, Cincinnati Eye Institute
May 11, 2020
OpRegen® Phase 1/2a Clinical Study Results
2020 ARVO Meeting
Christopher D. Riemann, M.D., Cincinnati Eye Institute (CEI)
Why is dry age-related macular degeneration (dry AMD) research so important?
Allen C. Ho, M.D., Wills Eye Hospital Director of Retina Research
Why is spinal cord research so important?
Dr. John Steeves, Emeritus Principal Investigator @ICORD and Professor @UBC
A selection of patient focused media related to our cell therapy programs
Sonia Cohen’s OpRegen Story
OpRegen for Dry AMD | Lineage Cell Therapeutics – Jul 27, 2021
OpRegen for Dry AMD | Lineage Cell Therapeutics – Jun 10, 2021
“New Treatment for Age-Related Dry Macular Degeneration” – May 10, 2021
5 years through the eyes of a mum.
A powerful dramatization of living with the progression of vision loss related to AMD. Source: www.macularsociety.org
Spinal Cord Injury and Lineage’s OPC1 Cell Therapy
An instructive whiteboard video explaining how spinal cord injury disrupts normal bodily function as well as OPC1 administration and mechanism of action.
OPC1 Program – Patient Spotlight
Highlighting the progress made by Kris Boesen and Lucas Lindner, both of whom received Lineage’s OPC1 cell therapy following traumatic spinal cord injury (SCI).
Lucas Lindner was paralyzed from the neck down following a car accident. The next year, he threw out the first pitch at a Major League Baseball game.
Watch the video above to learn more about Lucas’ journey.